Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19080581 | 0.80 | TDP1 (0.37) | TDP1MAPTCACNA1BAPBA1CYP3A4 | |
| SCHEMBL18756257 | 0.78 | TDP1 (0.36) | TDP1MAPTCACNA1BAPBA1CYP3A4 | |
| SCHEMBL5134780 | 0.74 | MAPT (0.39) | TDP1MAPTCACNA1BAPBA1CYP3A4 | |
| SCHEMBL18756267 | 0.74 | MAPT (0.36) | TDP1MAPTCACNA1BAPBA1CYP3A4 | |
| Glycerin SCHEMBL6834590 | 0.73 | MAPT (0.42) | TDP1MAPTCACNA1BAPBA1CYP3A4 | |
| Glycerin SCHEMBL8595519 | 0.72 | ALDH1A1 (0.39) | TDP1MAPTCACNA1BAPBA1CYP3A4 | |
| SCHEMBL19080580 | 0.72 | PYGL (0.30) | — | |
| SCHEMBL2070387 | 0.72 | MAPT (0.42) | TDP1MAPTCACNA1BAPBA1CYP3A4 | |
| Glycerin SCHEMBL10632349 | 0.71 | LMNA (0.38) | TDP1MAPTCACNA1BAPBA1CYP3A4 | |
| Glycerin SCHEMBL3140831 | 0.71 | LMNA (0.38) | TDP1MAPTCACNA1BAPBA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| EP-3156410-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | TDP1 4057/4885MAPT 2901/4885CACNA1B 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.